Trial Profile

A Prospective, Randomized, Open-Label Comparison of a Long Acting Basal Insulin Analog LY2963016 to Lantus in Combination with Mealtime Insulin Lispro in Adult Patients with Type 1 Diabetes Mellitus.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 22 Aug 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Insulin glargine (Primary) ; Insulin lispro
Indications Type 1 diabetes mellitus
Focus Registrational; Therapeutic Use
Acronyms ELEMENT-1
Sponsors Eli Lilly and Company

Most Recent Events

01 Aug 2018 Results from ELEMENT-1 and ELEMENT-2 studies published in the Diabetes Therapy
01 Jun 2017 Results of clinical outcomes in patients with patients with upper-quartile insulin antibody response data from two studies (ELEMENT-1 and ELEMENT-2) published in the Diabetes Therapy
09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com